科兴制药: 关于2024年限制性股票激励计划第一个归属期归属结果暨股份上市的公告

Core Points - The announcement details the results of the first vesting period of the 2024 restricted stock incentive plan for the company, with 1,615,000 shares set to be listed on July 16, 2025 [1][8] - The stock is part of an equity incentive program aimed at motivating employees and aligning their interests with those of shareholders [1][2] Summary by Sections Decision Process and Disclosure - The company’s board and supervisory committee have approved the relevant proposals regarding the 2024 restricted stock incentive plan, ensuring compliance with regulatory requirements [2][3] - The supervisory committee verified the list of incentive recipients and issued related opinions [2] Basic Information on Stock Vesting - A total of 127 individuals are eligible for the stock vesting, with 1,615,000 shares being made available for trading [5][8] - The stock originates from a directed issuance of A-share common stock to the incentive recipients [5] Listing and Capital Changes - The total number of shares outstanding will increase from 199,642,250 to 201,257,250 shares following the vesting [7] - The company has received a total of RMB 19,250,800 in subscription payments from the incentive recipients, with the capital increase properly registered [8] Financial Impact - The vesting of 1,615,000 shares represents approximately 0.81% of the total shares before the vesting, and it is expected to dilute earnings per share without significantly impacting the company's financial condition [8]